OPEN SOURCE DRUG DISCOVERY FOR CHIKUNGUNYA
N Vidya, Chetana Shetty, Mohan Deepa, Mayuri Rane, Pannuru Padmavathi, S Sandhya · 2014
used in the study which is monomer with molecular weight 50KDa which is anchored in the membrane of CHIKV. The structure of E1 was retrieved from Protein Data Bank. The PDB ID for E1 was 3N41 , which is responsible for Chikungunya virus replication. CHIKV replication is resistant to inhibition by interferon once RNA replication has been established and that CHIKV actively suppress the antiviral IFN response by preventing IFN-induced gene expression there by making host to shut-off [4,2] .The report have shown that the intensity of the infection has increased with every passing year with 45%–63% attack rates in world during outbreaks India is endemic to dengue fever and due to overlapping symptoms; CHIK infection is generally mistaken to be the former thereby leading to misdiagnosis. CHIKV infection is considered an important public health problem due to the morbidity and disability caused by chronic arthralgia [2] . The social and economic burden caused by CHIKV fever is tremendous. Hence, there is an urgent need for an effective vaccine or antiviral therapy against CHIKV infection. The Homology Modeling was used to predict the 3Dimensional structure of 3N41 [4] . Docking studies were carried out with various inhibitors and it was found that ligand 1IKW had a most stable interaction with 3n41. Indicate that LIGAND 1IKW is the most promising inhibitor for CHIKV. Keyword: CHIKV, drug design, OSDD, E1 protein, Efavirenz , Rimantidine